Results 231 to 240 of about 1,985,012 (310)

Systemic Treatment with Fas-Blocking Peptide Attenuates Apoptosis in Brain Ischemia. [PDF]

open access: yesInt J Mol Sci
Chung S   +12 more
europepmc   +1 more source

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm   +2 more
wiley   +1 more source

Temporal expression profiles of microRNAs associated with acute phase of brain ischemia in gerbil hippocampus. [PDF]

open access: yesHeliyon
Hamada Y   +11 more
europepmc   +1 more source

Early synovial regulatory T cell engagement in posttraumatic osteoarthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Posttraumatic osteoarthritis (PTOA) develops despite restoration of joint biomechanics, suggesting that early post‐injury biological processes within the synovium shape disease trajectories. We investigated whether synovial regulatory T (Treg) cells are engaged during the early phase following joint injury and whether experimental enrichment ...
Xueyou Zhang   +5 more
wiley   +1 more source

12-Hydroxyeicosatetraenoic acid is the only enzymatically produced HETE increased under brain ischemia. [PDF]

open access: yesProstaglandins Leukot Essent Fatty Acids
Golovko MY   +7 more
europepmc   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova   +5 more
wiley   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy